112 results match your criteria: "Sarcomatoid and Rhabdoid Renal Cell Carcinoma"
Primary tumor characteristics and immunohistochemical profile of renal cell carcinoma in serous fluid cytology.
J Am Soc Cytopathol
November 2024
Cytopathology Center of Excellence, Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Introduction: Renal cell carcinoma (RCC) involves serosal surfaces in 2%-3% of cases, and thus few papers describe serous fluid cytology (SFC) involvement by RCC. This diagnosis is challenging, given its rarity, nondescript cytomorphologic features and infrequent expression of widely used epithelial markers MOC31 and BerEP4. We describe our institutional experience with RCC in SFC specimens.
View Article and Find Full Text PDFCorrelation of histological immunophenotype in papillary renal cell carcinoma with gene signatures related to the therapeutic effect of systemic therapy.
Pathol Res Pract
December 2024
Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.
To predict the therapeutic response of systemic therapy, comprehensive analyses of the tumor microenvironment in papillary renal cell carcinoma (pRCC) have been conducted previously using immunohistochemistry and RNA sequencing. This study aimed to evaluate the correlation between hematoxylin and eosin-based histological immunophenotypes and gene signatures employed in several clinical trials predicting responsiveness to immune checkpoint inhibitors and tyrosine kinase inhibitors, using data from the Cancer Genome Atlas (TCGA)-KIRP cohort (n = 254). Herein, we evaluated tumor-associated immune cells (TAICs) using three methodologies previously reported in clear cell RCC: a 3-tier immunophenotype (desert, excluded, and inflamed) based on the spatial distribution of TAICs; a 4-tier immunophenotype (cold, immune-low, excluded, and hot) considering both the location and degree of TAICs; and an inflammation score (score 0, 1, and 2) focusing only on the degree of TAICs.
View Article and Find Full Text PDFHistopathological and immunohistochemical characteristics of adult renal tumors: a five-year retrospective study in Mureş County, Romania.
Rom J Morphol Embryol
November 2024
Department of Histology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureş, Romania;
Article Synopsis
- * Conducted at Mureş County Clinical Hospital in Romania, the research analyzed 220 patients who had nephrectomies over five years, revealing a predominance of malignant tumors, particularly clear cell renal cell carcinoma (CCRCC).
- * Findings indicate that the majority of patients were male (62.72%) with an average age of 62.63 years, and highlight the correlation between tumor characteristics like sarcomatoid features and poorer outcomes, contributing to the broader understanding of renal tumors.
Pattern of care and treatment outcomes of metastatic non-clear cell kidney cancer: a single centre experience from India.
Ecancermedicalscience
September 2024
Uro-Surgery, Tata Medical Center, 14 MAR (EW), New Town, Rajarhat, Kolkata 700160, West Bengal, India.
Background: Non-clear-cell renal cell carcinoma (nccRCC) refers to a rare diverse heterogeneous group of tumours; usually treated with immune check point inhibitors and or tyrosine kinase inhibitors (TKIs). Prospective large-scale data from Asian countries is limited.
Methods: This is a retrospective study of patients with metastatic nccRCC treated at Tata Medical Centre, Kolkata, India, from 2012 to 2022.
Renal cell carcinoma preceded by a rheumatoid‑like paraneoplastic syndrome: A case report.
Oncol Lett
October 2024
Nephrology Center, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa 213-8587, Japan.
Article Synopsis
- After a relapse two years later, he was switched to baricitinib, achieving remission again before RA recurred and he discovered a tumor in his kidney at age 72.
- Following surgical removal of the tumor, which was identified as renal cell carcinoma (RCC), the patient reported joint pain relief but ultimately died from systemic metastases about 10 weeks later, with the RA and RCC linked as a paraneoplastic syndrome.
Clinical T1/2 renal cell carcinoma: multiparametric dynamic contrast-enhanced MRI features-based model for the prediction of individual adverse pathology.
World J Surg Oncol
June 2024
Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
Article Synopsis
- The study investigates predictors of adverse pathology in cT1/2 renal cell carcinoma (RCC) using clinical data and multiparametric dynamic contrast-enhanced MRI (CEMRI) from 105 patients between 2018 and 2022.
- Adverse pathology was defined as worse conditions for patients, including high nuclear grade and certain aggressive types of RCC, and various CEMRI parameters were assessed for their predictive value.
- The developed predictive model showed strong diagnostic performance, with an area under the curve (AUC) of 0.907, identifying significant factors like gender and specific CEMRI findings as independent predictors of adverse pathology.
Sarcomatoid and Rhabdoid Renal Cell Carcinoma: Clinical, Pathologic, and Molecular Genetic Features.
Am J Surg Pathol
July 2024
Department of Pathology, Yale University School of Medicine, New Haven, CT.
Article Synopsis
- Renal cell carcinoma (RCC) with sarcomatoid and rhabdoid features exhibits aggressive behavior and poor prognosis, yet is not classified as a separate type in the 2022 WHO classification.
- Sarcomatoid RCC is characterized by malignant spindle cells, while rhabdoid cells display distinct eccentric nuclei and large inclusions, both showing unique molecular features that indicate a clonal evolution.
- New immunotherapy treatments targeting PD-1/PD-L1/CTLA-4 have shown promise, highlighting the importance of recognizing these specific tumor features for better management and treatment outcomes.
[2022 WHO classification of renal cell carcinomas: Focus on papillary renal cell carcinoma].
Ann Pathol
September 2024
Service d'anatomie et cytologie pathologiques, CHU de Rennes-Hôpital Pontchaillou, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex 9, France. Electronic address:
Renal cell carcinomas (RCC) represent a group of heterogeneous tumors whose classification has greatly evolved since 1981. The latest update in 2022 classifies all renal cell carcinomas into six categories according to their morphology or the detection of specific molecular alterations. Molecular disassembly of renal cell carcinomas with papillary features has enabled the identification of new entities characterized by a specific molecular alteration, such as Fumarate Hydratase (FH) deficient RCC, TFE3-rearranged RCC or TFEB-altered RCC.
View Article and Find Full Text PDFThe prognostic role of histomorphological subtyping in nonmetastatic papillary renal cell carcinoma after curative surgery: is subtype really irrelevant? A propensity score matching analysis of a multi-institutional real life data.
Urol Oncol
May 2024
Division of Urologic Oncology, Department of Urology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey.
Article Synopsis
- - This multi-institutional study aimed to investigate the prognostic impact of histomorphological subtyping in patients with nonmetastatic papillary renal cell carcinoma (papRCC) who underwent curative surgery, involving 1,086 patients categorized into two subtypes.
- - Results showed that patients with type 2 papRCC were generally older, had larger tumors, and exhibited poorer survival rates, with lower 5-year recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) than type 1 patients.
- - While type 2 was a significant predictor for RFS and CSS, it had no significant impact on OS, highlighting the need for further understanding of how these
World Health Organization 2022 Classification Update: Radiologic and Pathologic Features of Papillary Renal Cell Carcinomas.
Acad Radiol
August 2024
Department of Radiology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, California 94305, USA.
Article Synopsis
Sarcomatoid variant of Xp11 translocation renal cell carcinoma: A rare case report in an adult female.
Indian J Pathol Microbiol
February 2024
Chief of Uro Oncology, Shri Siddhivinayak Ganapati Cancer Hospital, Miraj, Maharashtra, India.
Xp11 translocation renal cell carcinoma (XPTRCC) is a very rare kidney neoplasm, which has been predominantly reported in young patients. Sarcomatoid transformation in renal cell carcinomas is known. However, its occurrence in XPTRCC is unreported so far in the literature.
View Article and Find Full Text PDFSuccinate Dehydrogenase Deficient Renal Cell Carcinoma With Sarcomatoid and Rhabdoid Features-A Diagnostic Dilemma.
Int J Surg Pathol
December 2024
Department of Pathology and Genomic Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Article Synopsis
- Succinate dehydrogenase (SDH)-deficient renal cell carcinoma (RCC) is a rare tumor with lower-grade characteristics but can exhibit aggressive features, as shown in a case of a 36-year-old woman who presented with severe symptoms and advanced disease.
- The patient's tumor displayed a mix of low-grade and high-grade features, including significant rhabdoid and sarcomatoid differentiation, leading to a poor prognosis despite the generally favorable outlook of SDH-deficient RCC.
- This case underscores the complexities of diagnosing high-grade tumors in SDH-deficient RCC and highlights the need for genetic testing and ongoing surveillance for related neoplasms due to the increased risk of metastasis.
CT features based preoperative predictors of aggressive pathology for clinical T1 solid renal cell carcinoma and the development of nomogram model.
BMC Cancer
January 2024
Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Article Synopsis
- The study aimed to identify predictors of aggressive pathology in cT1 solid renal cell carcinoma (RCC) by integrating clinical features and CT scan data to create a nomogram model.
- In a retrospective analysis of 776 RCC patients, key factors such as neutrophil-to-lymphocyte ratio, tumor characteristics, and CT findings were found to significantly predict aggressive pathology, with 32.2% of patients exhibiting such features.
- The nomogram developed from these predictors showed strong accuracy, with an area under the curve of 0.854, suggesting its potential utility in clinical decision-making for RCC treatment.
Understanding Factors that Influence Prognosis and Response to Therapy in Clear Cell Renal Cell Carcinoma.
Adv Anat Pathol
March 2024
Department of Pathology.
In this review, we highlight and contextualize emerging morphologic prognostic and predictive factors in renal cell carcinoma. We focus on clear cell renal cell carcinoma (ccRCC), the most common histologic subtype. Our understanding of the molecular characterization of ccRCC has dramatically improved in the last decade.
View Article and Find Full Text PDFGrowth kinetics of venous tumor thrombus in patients with renal cell carcinoma.
Urol Oncol
February 2024
Division of Urologic Surgery, Department of Surgery, Washington University in St. Louis, MO.
Article Synopsis
- * Researchers analyzed preoperative imaging from 30 patients to measure VTT growth, finding an average growth rate of 0.3 mm per day, with certain tumor types showing faster growth.
- * The findings highlight the importance of timely surgical intervention and suggest that specific tumor characteristics can predict VTT growth, calling for further research in this area.
Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.
Oncologist
May 2024
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Article Synopsis
- Metastatic renal cell carcinoma (RCC) with sarcomatoid and/or rhabdoid dedifferentiation shows aggressive behavior but responds better to immune checkpoint therapy (ICT), although outcomes with VEGFR-targeted therapies after ICT progression were previously unclear.
- A study reviewed 57 patients with various levels of sarcomatoid (S) and rhabdoid (R) dedifferentiation who received VEGFR-targeted therapies after failing ICT, assessing metrics like time on treatment, overall survival, and response rates.
- Results indicated that patients with R dedifferentiation experienced longer treatment durations and better outcomes compared to those with S dedifferentiation, suggesting that R dedifferentiation may respond more favorably
Cutaneous metastasis of a sarcomatoid-rhabdoid renal tumor to a distal phalanx.
Int J Dermatol
February 2024
Department of Dermatology, Hospital Universitario Infanta Sofía, Madrid, Spain.
Morphological characteristics of SETD2-mutated locally advanced clear cell renal cell carcinoma: Comparison with BAP1-mutated clear cell renal cell carcinoma.
Ann Diagn Pathol
February 2024
Department of Pathology, Genitourinary Pathology Center of Excellence, University of Pittsburgh Medical Center, Pittsburgh, USA.
Article Synopsis
- SETD2 and BAP1 are chromatin remodeling genes that are frequently mutated in clear cell renal cell carcinoma (ccRCC) and play a role in tumor progression and metastasis.
- A study compared 7 cases of locally advanced ccRCC with SETD2 mutations to 7 cases with BAP1 mutations, finding that SETD2-mutated tumors exhibited aggressive growth with a rhabdoid morphology and significant invasive characteristics.
- The study emphasizes the importance of molecular testing for SETD2 and BAP1 mutations in ccRCC for better risk assessment and treatment strategies, as their high-grade features can overlap, making it challenging to identify the mutations based solely on tumor appearance.
Clear cell renal cell carcinoma with mutation: a report of two cases.
Am J Clin Exp Urol
October 2023
Pathology and Laboratory Medicine Service, Overton Brooks VA Medical Center Shreveport, LA, USA.
Article Synopsis
- - Clear cell renal cell carcinoma (RCC) is the most prevalent type of kidney cancer, making up 60%-70% of adult cases, and is strongly linked to mutations in the von Hippel-Lindau gene on chromosome 3p, found in over 90% of cases.
- - Other tumor suppressor genes on chromosome 3p also play a role in the development of these tumors, with specific mutations leading to unique histopathological characteristics.
- - The report details two cases of clear cell RCC with distinct mutations, highlighting aggressive features, including high-grade nuclei, eosinophilic granules, and the presence of rhabdoid and sarcomatoid cells, indicating a severe clinical outcome.
Surgical Management and Oncologic Outcomes of Renal Cell Carcinoma and Inferior Vena Caval Thrombi With Aggressive Histologic Variants.
Urology
February 2024
Cleveland Clinic Glickman Urological and Kidney Institute, Department of Urology, Cleveland, OH.
Article Synopsis
- The study aims to analyze the surgical treatment, perioperative outcomes, and the impact of aggressive histologic variants (AHV) in patients with renal cell carcinoma (RCC) and inferior vena cava (IVC) thrombus, noting that AHV indicates a poorer prognosis.* -
- Researchers reviewed data from 403 patients who underwent surgery from 1990 to 2020, finding that 23.3% had AHV and were more likely to show advanced disease stages, but surgery did not lead to worse perioperative outcomes.* -
- Results indicated that while the median survival was similar for patients with and without AHV, sarcomatoid differentiation significantly worsened overall survival, highlighting the need for careful evaluation in surgical
High XB130 expression in renal cell carcinoma is strongly associated with poor prognosis.
Ann Diagn Pathol
December 2023
Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. Electronic address:
Article Synopsis
- The study examined the role of XB130 expression in three types of renal cell carcinoma (RCC) and its impact on patient outcomes using 101 nephrectomy samples from a Thai hospital.
- Results indicated that high XB130 levels in clear cell and papillary RCC were linked to poorer prognosis and several adverse clinical features, including higher tumor grades and the presence of metastasis.
- The findings suggest that XB130 expression serves as an independent risk factor for mortality, highlighting its potential as a prognostic marker in RCC patients.
[Ga]Ga‑LNC1007 PET/CT in the evaluation of renal cell carcinoma: comparison with 2-[F]FDG/[Ga]Ga-PSMA PET/CT.
Eur J Nucl Med Mol Imaging
January 2024
Department of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, Fujian Province, China.
Article Synopsis
- The study compares the efficiency of [Ga]Ga-LNC1007 PET/CT with 2-[F]FDG and [Ga]Ga-PSMA PET/CT in detecting renal cell carcinoma (RCC) among 25 confirmed patients.
- Results show that [Ga]Ga-LNC1007 PET/CT has a significantly higher detection rate and better metrics (like SUV and TBR) compared to the other two methods.
- Additionally, parameters derived from [Ga]Ga-LNC1007 PET/CT can effectively differentiate between various pathological characteristics of RCC, indicating its potential as a valuable imaging tool.
Head-to-head comparisons of enhanced CT, 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in identifying adverse pathology of clear-cell renal cell carcinoma: a prospective study.
Int Braz J Urol
November 2023
Department of Urology, Urology Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Article Synopsis
- The study aims to evaluate the effectiveness of different imaging techniques (enhanced CT, 68Ga-PSMA-11 PET/CT, and 18F-FDG PET/CT) in predicting aggressive pathology in clear-cell renal cell carcinoma (ccRCC) prior to surgery.
- It involved a prospective analysis of 72 patients with newly diagnosed renal masses who underwent these imaging techniques before nephrectomy, excluding those with certain conditions or who refused treatment.
- Results indicated that enhanced CT was less effective in detecting adverse pathology compared to 68Ga-PSMA-11 PET/CT, which showed a significantly higher ability to identify tumor necrosis and unfavorable characteristics.
Clear Cell Renal Cell Carcinoma With Syncytial-Type Multinucleated Giant Tumor Cells: A Clinicopathologic Study of 14 Cases.
Int J Surg Pathol
June 2024
Department of Pathology, Stanford University, Stanford, CA, USA.
The presence of syncytial-type multinucleated giant tumor cells with emperipolesis in clear cell renal cell carcinoma (RCC) is uncommon, with only 31 cumulative published cases to date. After a rereview of 125 clear cell RCC of World Health Organization/International Society of Urological Pathology grade 3 or 4, 14 clear cell RCCs with admixed syncytial-type giant cells (to our knowledge, the largest series to date) were found with a mean patient age of 67 years and with no sex difference (M = 7, F = 7). Mean tumor size was 7.
View Article and Find Full Text PDFComparison of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma with rhabdoid and sarcomatoid differentiations.
Cancer Med
July 2023
Key Laboratory of Cancer Prevention and Therapy, Department of Geniturinary Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Article Synopsis
- - This study aimed to evaluate how effective tyrosine kinase inhibitors (TKIs) are for treating metastatic renal cell carcinoma (mRCC) with two specific types of tumor differentiations: rhabdoid (mRCC-R) and sarcomatoid (mRCC-S).
- - Out of 111 patients with these mRCC differentiations, 23 were fully analyzed, revealing that mRCC-R had a median progression-free survival of 19 months and a median overall survival of 32 months, while mRCC-S had poorer outcomes with a progression-free survival of 7 months and overall survival of 21 months.
- - The results suggest that patients with mRCC-S have a worse